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TBK1: a new player in ALS linking
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Abstract
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disorder affecting motor neurons, resulting
in progressive muscle weakness and death by respiratory failure. Protein and RNA aggregates are a hallmark of ALS
pathology and are thought to contribute to ALS by impairing axonal transport. Mutations in several genes known
to contribute to ALS result in deposition of their protein products as aggregates; these include TARDBP, C9ORF72,
and SOD1. In motor neurons, this can disrupt transport of mitochondria to areas of metabolic need, resulting in
damage to cells and can elicit a neuroinflammatory response leading to further neuronal damage. Recently, eight
independent human genetics studies have uncovered a link between TANK-binding kinase 1 (TBK1) mutations and
ALS. TBK1 belongs to the IKK-kinase family of kinases that are involved in innate immunity signaling pathways;
specifically, TBK1 is an inducer of type-1 interferons. TBK1 also has a major role in autophagy and mitophagy, chiefly
the phosphorylation of autophagy adaptors. Several other ALS genes are also involved in autophagy, including p62
and OPTN. TBK1 is required for efficient cargo recruitment in autophagy; mutations in TBK1 may result in impaired
autophagy and contribute to the accumulation of protein aggregates and ALS pathology. In this review, we focus
on the role of TBK1 in autophagy and the contributions of this process to the pathophysiology of ALS.
Keywords: TBK1, Amyotrophic lateral sclerosis, ALS, Motor neuron disease, Autophagy, Mitophagy, Neuroinflammation,
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Introduction
ALS is a multifactorial disorder with diverse genetic
and environmental components [1]. The median inci-
dence rate of ALS is approximately 2/100000 [2], of
which 5–10% are familial (fALS). The mean age of
onset of ALS is between 50 and 65 years with death oc-
curring on average 2–3 years post-onset, due to respira-
tory failure [3]. Riluzole is currently the only drug
available for treatment of ALS [4]; its modest thera-
peutic value highlights the imminent need for novel
ALS treatments. Environmental factors linked to ALS
include smoking and exposure to chemicals metals and
radiation [5]. These factors are thought to contribute to
ALS by a number of mechanisms; an important com-
mon factor is increased oxidative stress in neurons.
Other mechanisms include damage to mitochondria,
neurotoxicity and increased glutamate excitotoxicity by
heavy metals (particularly lead) and cigarette smoke [3].
Mutations in more than 40 genes are thought to con-
tribute to the disease. Amongst the most prevalent
causes are SOD1, C9ORF72, TARDBP, FUS, OPTN and
the most recently identified ALS gene TANK-binding
kinase 1 (TBK1) [1, 6, 7].
TBK1 as an ALS gene
Genetic alterations in TBK1 (also known as NAK or T2K)
were initially associated with diseases with known neu-
roinflammatory components, including two forms of
glaucoma: primary open angle glaucoma and normal ten-
sion glaucoma. Increased TBK1 copy number resulting in
a gain of function is recognized as a rare cause of these
diseases [8, 9]. Heterozygous loss of function TBK1 muta-
tions are also associated with herpes simplex encephalitis
in childhood and it has been suggested that this is due to
decreased activity in TLR3 mediated immunity [10].
TBK1 was first identified as an ALS gene by two
independent studies. Cirulli et al. [6] performed exome
sequencing on 2869 ALS patients and 6405 controls of
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genetically European ethnicity and analyzed variants
using a number of inheritance models. This study con-
firmed several previously identified ALS genes and iden-
tified TBK1 as a novel ALS gene [6]. Freischmidt et al.
[7] performed exome sequencing and a targeted muta-
tion screen using high resolution melting curve analysis
which identified TBK1 as an ALS gene in a Swedish
population. Subsequently, a study of Australian fALS
patients identified a novel TBK1 mutation in a family of
Chinese origin, the first TBK1 mutation found in an
Asian ALS patient [11]. This study did not find any
TBK1 mutations in patients of European ancestry and
concluded that TBK1 mutations are rare in Australian
fALS patients [11]. More recently, TBK1 mutations have
been found to be a rare cause of ALS in Taiwanese and
Chinese populations [12, 13], as well as in Sardinian
ALS patients [14]. Frontotemporal dementia (FTD) is a
neurodegenerative disorder closely linked to ALS and
many patients present with both conditions. In a study
of ALS and FTD patients in a French population, TBK1
mutations occurred more frequently in patients with
FTD-ALS comorbidity (10.8%) than in those with ALS
alone (0.5%) [15–17]. Several other studies have identi-
fied TBK1 mutations to be a major cause of FTD either
concurrent with or without ALS [12, 14].
These human genetic studies identified nonsense, frame-
shift, missense and deletion mutations in both sporadic
and familial ALS cases (and ALS-FTD/FTD) dispersed
throughout the TBK1 protein sequence (Fig. 1a). Nonsense
and frameshift mutations cause major disruption to TBK1
and may decrease its expression at both the mRNA and
protein level [7, 17], implying that TBK1 haploinsufficiency
contributes to the development of ALS in these cases.
However, the contribution of missense mutations and
single amino acid deletions are more subtle, as they may or
may not confer either loss of function or reduction in func-
tion. These variants are also less likely to cause a decrease
in expression suggesting haploinsufficiency is not to blame
in these cases. Elucidation of the functional effects of these
variants will contribute to our understanding of ALS
pathogenesis as well as TBK1 function as discussed below.
Molecular pathology of ALS
ALS involves the premature loss of upper and lower
motor neurons, with degeneration of these neurons in the
spinal cord, brainstem and motor cortex [3]. This leads to
weakening and atrophy of muscles and eventually paraly-
sis [1, 3]. At the molecular level, numerous factors affect
ALS pathology including RNA and protein aggregates,
mitochondrial dysfunction and neuroinflammation.
Protein and RNA aggregates
The presence of protein and RNA aggregates in the
cytoplasm of motor neurons is the primary hallmark of
ALS. The most common protein inclusion in ALS is
TDP-43 (encoded by TARDBP). TARDBP mutations are
a cause of both fALS and sporadic ALS (sALS); however,
mutations are not a requirement for formation of aggre-
gates, which may be formed from wild-type proteins.
TDP-43 is an RNA-binding protein normally found in
the nucleus where it has roles in gene expression and
RNA processing. However, cytoplasmic aggregates of
TDP-43 are frequently observed in ALS and these are
often ubiquitinated [1].
C9ORF72, which has roles in stress granule formation,
microglial function and autophagy [18–20], contains a
hexanucleotide GGGGCC repeat in its first intron; ex-
pansion of this repeat is the most frequent cause of fALS
[21]. In healthy individuals, the repeat is <30 copies in
length, however, in ALS patients the number of repeats
may be expanded to hundreds of copies. C9ORF72 ex-
panded repeats result in three types of inclusion: intra-
nuclear RNA foci, cytoplasmic C9ORF72 aggregates,
(which may colocalize with p62 and TDP-43), and di-
peptide repeat proteins produced by RAN-translation
of the expanded region [1, 22]. These abnormal protein
aggregates are thought to be the mechanism by which
Fig. 1 a Primary structure of TBK1. TBK1 is 729 amino acids in length
and comprises four main domains: a kinase domain (KD), ubiquitin-like
domain (ULD) and two coiled-coil domains (CCD1 and CCD2). Locations
of TBK1 mutations associated with ALS and ALS-FTD are indicated
by vertical lines: Black – frame shift mutations, orange – nonsense
mutations, green – Missense mutations, blue – in-frame deletions,
purple – splice mutations and yellow - insertion mutations. b
Tertiary structure of TBK1. The region highlighted in red represents the
kinase domain, the turquoise region represents the ubiquitin-like
domain and the yellow region represents coiled-coil domain 1.
Coiled-coil domain 2 is not shown in this model. Diagram produced
in PyMOL using crystal structure data published by Larabi et al.
2013 [40] accessed via protein databank (accession number: 4IWO).
(RCSB Protein Data Bank, 2016)
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C9ORF72 expanded repeats contribute to ALS. C9ORF72
transcription in heterozygous 311005021Rik (C9ORF72
mouse ortholog) knock-in C57BL/6 mice is highest in neu-
rons of the hippocampus, cerebellum, cortex, brainstem
nuclei and striatum, all of which are known to degenerate
in ALS and FTD [23]. This suggests that C9ORF72 repeat
expansion related pathology would be most potent in these
regions, providing some insight into the cell-specificity of
neuronal degeneration in C9ORF72-ALS.
SOD1 was the first ALS gene identified and it is widely
studied due to the availability of the SOD1-G93A mouse
model of ALS [24]. Mutations in SOD1 produce an
unstable protein which is deposited in the cytoplasm;
oligomerisation of unstable SOD1 leads to aggregate
formation [25]. FUS is another RNA binding protein in
which mutations can result in the formation of cytoplas-
mic aggregates. It is a component of stress granules and
may form p62 and TDP-43 positive aggregates [1]. TDP-
43 positive protein inclusions, as well as C9ORF72
repeat expansion pathologies, are also involved in FTD
and ALS-FTD.
The mechanism by which these inclusions contribute
to ALS and FTD pathogenesis is as yet undefined,
though they are thought to impair axonal transport [3].
It is also unclear as to whether the inclusions them-
selves are cytotoxic or if they are secondary to another
primary pathology [1, 22]. It is postulated that impaired
autophagy could be a contributing factor to the accu-
mulation of cytoplasmic aggregates [26]. TBK1 has im-
portant roles in autophagy [27] and it seems likely that
it is by this mechanism that TBK1 mutations contribute
to ALS.
Mitochondrial dysfunction
Mitochondria have important roles in cellular respir-
ation, calcium buffering and apoptosis. Neurons are par-
ticularly sensitive to mitochondrial dysfunction given
their high metabolic rate [28] and the presence of abnor-
mal or dysfunctional mitochondria in neurons is thought
to be a contributing factor in ALS. The presence of mu-
tant SOD1 in the cytoplasm of motor neurons plays a
major role in mitochondrial dysfunction resulting in
impaired ATP production, impaired calcium buffering
and early apoptosis of neuronal cells [29–31]. Calcium is
critical to the correct functioning of motor neurons as it
has major roles in metabolism, development, and syn-
aptic transmission. Early apoptosis is brought about by
the interaction of SOD1 and mitochondrial apoptotic
machinery, this process directly contributes to motor
neuron degeneration [32].
Transport of substances along the length of motor
neurons is crucial for normal function and disruption of
axonal transport of mitochondria has been observed
in both ALS patients and animal models [33, 34].
Mitochondria are transported along motor neurons to
areas of greatest metabolic need and calcium regula-
tion; disruption of this process leads to reduced ATP
availability and dysregulation of calcium levels result-
ing in neuron damage. Disruption of axonal transport
also potentiates the accumulation of protein and RNA
aggregates discussed above, this leads to further im-
pairment of axonal transport resulting in motor neuron
degeneration [3]. Damage to motor neurons as a result of
protein aggregate accumulation and mitochondrial
dysfunction leads to secondary non-neuronal cell
causes of motor neuron degeneration such as neuro-
inflammation [1].
Neuroinflammation
Glial cells are the principle innate immune cell of the
CNS and pathology associated with these cells is referred
to as neuroinflammation [35], a hallmark of ALS. Glial
cells primarily express the Toll-like receptors TLR3 and
TLR4 [36]; ligand binding results in activation and mi-
gration of glial cells towards sites of damage where they
dispose of damaged cells through phagocytosis. A by-
product of this process is the production of neurotoxic
molecules such as pro-inflammatory cytokines and
reactive oxygen species. These molecules may cause
further neuronal damage leading to further glial cell acti-
vation resulting in a positive feedback loop of neuroin-
flammation [35]. TBK1 is involved in the innate immune
response by regulating the production of IFNα and
IFNβ. Ligand binding of TLR3 or TLR4 results in re-
cruitment of adaptor proteins TRIF and TRAM. TRIF
interacts with TRAF3 resulting in activation of TBK1/
IKKi hetero- or homo-dimers which in turn phosphoryl-
ate IRF-3 and IRF-7 allowing the formation of homodi-
mers. IRF-3/IRF-7 homodimers are transported to the
nucleus where they act as transcription factors for
IFNα and IFNβ [37]. TBK1 is also involved in TLR in-
dependent antiviral signaling involving intracellular
RIG-I-like receptors (RLRs). Ligand binding of RLRs
leads to TBK1 activation through a complex pathway
involving the outer mitochondrial membrane (OMM)
protein MAVS and the adaptor protein STING [38].
T cells have been observed in spinal cord lesions of
ALS patients and are thought to play a role in the regu-
lation of neuroinflammation. CD4+ cells stabilize micro-
glial activation, decrease pro-inflammatory cytokines and
increase growth factor IGF-1 suggesting that T cells play
a protective role in ALS [35]. Migration of T cells from
the lymph nodes is impaired in TBK1 knockout mice
[39], potentially resulting in decreased T cell number in
the CNS. This may increase the damage caused by neu-
roinflammation by removing the protective regulation by
T cells.
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TBK1 structure and function
Protein structure and regulation
TBK1 contains four domains: a serine/threonine kinase
domain (KD) (residues 1–307) located at its N-terminal, a
ubiquitin-like domain (ULD) (residues 308–383) and two
coiled-coil domains, coiled-coil domain 1 (CCD1) (residues
407–657) and coiled-coil domain 2 (CCD2) (residues
658–713) http://www.uniprot.org/uniprot/Q9UHD2 [40].
(Fig. 1). CCD1 is also referred to as a scaffold dimerization
domain (SDD) [7, 40, 41]. TBK1 may form a homodimer
or a heterodimer with IKKi; formation of a homodimer is
primarily mediated by interactions between the two CCD1
domains however, the KDs and ULDs also interact with
the adjacent molecule. The interacting residues forming
the dimer are conserved and are required for activation, a
process that requires TBK1 dimerisation [42].
The KD is comprised of two lobes termed N-terminal
and C-terminal lobes, with the active site situated
between these two lobes. The KD also contains an acti-
vation loop (Leu164-Gly199) which includes Ser172,
phosphorylation of which brings about TBK1 activation.
In the inactive form, the activation loop protrudes away
from the KD towards the C-lobe of the KD of the other
TBK1 protein comprising the dimer. A conserved resi-
due, Glu55, is also displaced from the active site. It is
speculated that TBK1 dimers are able to autophosphory-
late through the interaction of adjacent KDs and activa-
tion loops. Phosphorylation of Ser172 results in a
conformational change of the activation loop. The acti-
vation loop retracts towards and interacts with its own
KD allowing substrate binding. The conserved Glu55 resi-
due is also rotated into a position where it can form a salt
bridge with Lys38. Other than this, conformational
changes as a result of phosphorylation are limited [40, 43].
Poly-ubiquitination of Lys30 and Lys401 is a require-
ment for activation of TBK1 and a multistep mechanism
of TBK1 activation beginning with poly-ubiquitination
of Lys30 and Lys401 followed by phosphorylation of
Ser172 has been suggested [42]. This results in a con-
formational change of the active site to allow substrate
binding. Along with the KD, the ULD is also important
for the kinase activity of TBK1; deletion of the ULD re-
sults in a loss of kinase activity [44]. Sequence alignment
of the TBK1 ULD with similar human ULDs and ULDs
of TBK1 from other species has identified many struc-
turally important conserved residues. Three residues,
Leu316, Ile353, and Val382, are suspected to be involved
in protein-protein interactions [41]. These residues form
a hydrophobic patch homologous to the hydrophobic
patch of ubiquitin (Leu316, Ile44, and Val70) [41]. Ubi-
quitin interacts with its binding partners via this hydro-
phobic patch, indicating that TBK1 may also interact
with proteins via this structure. The hydrophobic patch
is also thought to be involved in interactions between
the TBK1 ULD and CCD1. Comparison of the surface
charge of various regions of ULDs of IKK-family ki-
nases reveals that it differs between family members
and these differences may determine substrate specifi-
city [41]. Mutations around the hydrophobic patch have
been demonstrated to prevent activation of downstream
molecules of TBK1 [41].
TBK1 is regulated by adaptor proteins that control its
localization, activation and participation in different sig-
naling pathways [45, 46]. TBK1 possesses the ability to
robustly autophosphorylate, and therefore requires strict
regulation. This, alongside the fact that TBK1 plays roles
in many pathways including induction of interferons and
autophagy, means that the subcellular localization of
TBK1 may contribute to its regulation as well as its sig-
naling specificity [47]. NAP1, TANK, and Sintbad are
adaptor proteins that bind to the CCD2 domain of
TBK1. These adaptor proteins bind in a mutually exclu-
sive manner and the differing subcellular localization of
these adaptors may determine the pathway in which
TBK1 will participate [46]. This is supported by findings
that TBK1 activated in autophagy does not result in acti-
vation of its downstream targets in the innate immunity
signaling, this suggests that there is limited crosstalk
between the different TBK1 pathways [48]. NAP1 and
Sintbad are localized diffusely throughout the cytoplasm
whereas TANK is punctate in the perinuclear region, this
has led to suggestions that binding of TANK results in
the induction of IFNα and IFNβ whereas binding of
NAP1 or Sintbad is more important for autophagy [49].
A network of 30 proteins interacting with one or more
of these adaptor proteins and/or TBK1/IKKi has been
established [46]. This all suggests that adaptor binding
to TBK1 plays a key role in its activation and function
within the cell.
TBK1 mutations
We collated 92 TBK1 mutations identified in patients
with ALS, ALS-FTD or FTD from eight human genetics
studies (Table 1, Additional file 1: Table S1 and Fig. 1).
88 of these mutations were identified in ALS patients
(ALS and ALS with FTD) of which 27 are potential loss
of function variants (nonsense, splice site and frameshift
Table 1 Breakdown of TBK1 mutations by disease type and
protein domains
Domain
Disease Kinase domain Ubiquitin-like
domain
CCD1 CCD2
ALS 32 (84%) 11 (100%) 29 (71%) 2 (25%)
ALS-FTD 2 (5%) 0 (0%) 9 (22%) 4 (50%)
FTD 4 (11%) 0 (0%) 3 (7%) 2 (25%)
Total no. cases 38 11 41 8
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mutations) and 16 are in-frame insertions/deletions.
Freischmidt et al. identified 8 heterozygous loss of func-
tion variants, of which 7 resulted in the loss of expres-
sion of TBK1 and therefore were reported as causative
via haploinsufficiency [7]. The loss of function variant
that was expressed (p.690-713del) contained a deletion in
the CCD2 domain that prevented binding of OPTN, indi-
cating that this may be sufficient to cause ALS/FTD [7].
The majority of ALS-associated TBK1 variants (45)
identified to date are missense mutations (Fig. 2,
Additional file 1: Table S1) of unknown pathogenicity.
The functional relevance of these variants is less obvious
than nonsense or frameshift mutations, which lead to loss
of expression of TBK1. Missense mutations may be patho-
genic if the site is crucial to the function or stability of the
protein. Mutations in the KD may affect phosphoryl-
ation of substrates whereas mutations within the ULD
may affect recruitment to ubiquitinated proteins and
organelles. CCD1 is important for TBK1 dimerisation
and mutations here could affect this process, which is
required for TBK1 activation [42]. CCD2 domain muta-
tions could interfere with adaptor binding and TBK1
activation [46].
Mutations in the KD and CCD1 account for a greater
proportion of disease cases than mutations in the ULD
or CCD2 (Table 1, Additional file 1: Table S1) but when
domain size is taken into account, mutations are evenly
distributed across all domains of TBK1 (Fig. 1). KD,
ULD and CCD1 mutations occur more frequently in
ALS cases whereas CCD2 mutations seem more likely to
result in ALS-FTD or FTD. However, larger numbers of
patients with TBK1 mutations are needed to confirm
any potential domain-specific associations. Using tools
to predict the functional effects of mutations, the largest
proportion of missence mutations that are probably
damaging, occur in the kinase domain (Additional file 1:
Table S1). However, biochemical analysis of variants
located in each domain of TBK1 revealed functional
deficits in TBK1 in four out of five cases, indicating that
many missence mutations have the potential to be
pathogenic [7]. Determining which TBK1 missence mu-
tations cause selective loss of function of TBK1 could
shed light on the functions of TBK1 most relevant to
disease.
Autophagy and the role of TBK1
Autophagy
Autophagy is a process by which ubiquitinated proteins
and damaged organelles are degraded and recycled.
Abnormal protein aggregates are a hallmark of ALS
pathology, in addition to this, mutations in several genes
involved autophagy have been associated with ALS includ-
ing SQSTM1 (encodes p62), SOD1, OPTN,VCP, UBQLN2
and most recently TBK1. This suggests that disruption of
autophagy is important in ALS pathophysiology [1, 50].
Autophagy begins with the formation of an immature
membrane structure called a phagophore in response to
signaling initiated by phosphorylation of the ULK1-
ATG13-FIP200 complex [51]. This is normally inhibited
by mTORC1, however, the action of mTORC1 can, in
turn, be inhibited by AMPK [26]. The activated ULK1-
ATG13-FIP200 complex triggers movement of another
complex containing beclin1 and PI3K CIII towards a
phagophore. This complex mediates elongation of the
phagophore membrane and envelopment of proteins or
organelles marked for degradation, resulting in the for-
mation of a double-membrane bound autophagosome.
The process of autophagosome formation is also medi-
ated by two interlinked control systems, the Atg5-Atg12
conjugation system [52] and the microtubule-associated
protein 1A/1B LC3 conjugation system [53]. The Atg5-
Atg12 conjugation system results in the formation of a
complex of Atg5-Atg12-Atg16. This complex allows
conjugation of LC3 with phosphatidyl-ethanolamine to
produce LC3-II [50], which then binds to the surface of
a phagophore where it has roles in elongation and
cargo recruitment [26]. The autophagosome is trans-
ported along a microtubule to a lysosome-rich area.
The autophagosome fuses with a lysosome forming an
autophagolysosome, the contents of which are digested
[50] (Fig. 3).
Autophagy adaptors enhance disposal of cargo, such
as ubiquitinated proteins and damaged mitochondria, by
linking them with autophagosome-associated proteins
such as LC3-II [50]. Many of the ALS-associated inclu-
sions described previously contain p62 and ubiquitin.
Ubiquitination of proteins marks them for degradation;
autophagy adaptors recruit ubiquitinated proteins to the
phagophore by linking ubiquitin and LC3-II. p62 and
Fig. 2 Frequency of different types of ALS and FTD-associated TBK1
mutations. Summary of data compiled in Additional file 1: Table S1
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OPTN are autophagy adaptors and mutations in these
proteins result in impaired autophagy and are recog-
nized causes of ALS [54, 55]. Importantly, p62, OPTN,
and another autophagy adaptor NDP52 are all regulated
by phosphorylation by TBK1 [48].
The presence of abnormal protein inclusions in the
brain is a common feature of ALS and neurons can re-
spond to this accumulation by upregulating autophagy
[56]; if autophagy is disrupted, this may contribute to
neurodegeneration and the pathology of ALS. This
hypothesis is supported by the loss of autophagy in the
CNS of Atg7−/− and Atg5−/− mice (two genes essential
for autophagy), resulting in neurodegenerative disease
[57, 58]. Loss of neurons, increased apoptosis and in-
creased protein aggregation were evident when autophagy
was decreased [57, 58]. The fact that several ALS genes
are involved in autophagy and the knowledge that forma-
tion of protein aggregates contribute to ALS pathogenesis,
suggests that disruption of autophagy is of importance to
the development of ALS. The various roles of TBK1 in
autophagy, especially adaptor phosphorylation, suggests
that this may also be an important process in the contri-
bution of TBK1 mutations to ALS.
TBK1 also plays a role in innate immunity, chiefly the in-
duction of type-I interferons, alongside its aforementioned
role in autophagy. These roles seem to be largely distinct
and only limited crosstalk is evident. Interferons, induced
by TBK1, lead to the transcription of interferon-inducible
genes, amongst the targets of type-I interferons is ISG15,
which has been linked to autophagy [59, 60]. ISG15 inter-
acts with p62 and HDAC6, a protein with roles in cargo
aggregation and autophagolysosome formation [61]. Over-
expression of ISG15 results in enhanced aggregate forma-
tion and autophagy [60]. ISG15 can also suppress
autophagy by binding beclin1 and PI3K CIII [59]; proteins
important in phagophore elongation [26]. Loss of TBK1
decreases ISG15 and therefore removes its suppression of
autophagy. In addition to this, enhanced aggregate forma-
tion was only observed with overexpression of ISG15
[60]. These factors suggest that ISG15 related mecha-
nisms are probably not important in the contribution
of mutant TBK1 to ALS; however, this highlights an
interesting link between two TBK1 pathways.
Autophagy, TBK1 and ALS pathogenesis
TBK1 plays key roles in autophagy, including the phos-
phorylation of a number of autophagy adaptors including
p62, OPTN and NDP52 [48], enhancing their ability to
link LC3-II and ubiquitinated cargo (Fig. 3) [26]. Phos-
phorylation of OPTN and p62 involves interaction with
Fig. 3 Autophagolysosome formation and maturation. Autophagy involves the formation of an isolation membrane. This membrane undergoes
elongation, forming a phagophore and a portion of the cytoplasm is separated to form an autophagosome. This involves the ULK1-ATG13-FIP200,
Beclin1-PI3K CIII and Atg5-Atg12-Atg16 complexes The autophagosome fuses with a lysosome to form an autophagolysosome, allowing digestive
enzymes to degrade any material in the vesicle. TBK1 binds and phosphorylates autophagy receptors OPTN and p62; they bind to ubiquitin residues
on target cargo and to LC3-II. This enhances the ability of the receptors to bind ubiquitinated residues on target cargo and LC3-II. This all allows
ubiquitinated cargo to be recruited to the phagophore for degradation; the receptors act as adaptors that link cargo to autophagic machinery
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the CCD2 domain of TBK1 [15]. Several TBK1 mutations
identified in ALS patients cause protein truncation
resulting in loss of CCD2 [7], decreasing the ability of
TBK1 to phosphorylate these molecules. In addition to
this, some TBK1 mutations result in decreased mRNA
and protein levels [7, 17], which may decrease activation
of autophagy adaptors, resulting in decreased autophagy
and accumulation of protein aggregates in motor neurons.
TBK1 has also been implicated in autophagosome
maturation. In TBK1 knockdown cells, autophagosome
formation was not disrupted whereas maturation of
autophagosomes into autophagolysosomes was inhibited
[27]. Rab8b is an upstream regulator of TBK1 and they
both colocalize with LC3 on autophagosomes; this inter-
action is proposed as a mechanism by which TBK1 is in-
volved in autophagosome maturation [27]. Maturation
of autophagosomes involves transport to a lysosome-rich
area via microtubules, this is dependent on the action of
the motor protein dynein [62]. TBK1 regulates micro-
tubule dynamics in mitosis and the cytoplasmic levels of
dynein [63]. Disruption of microtubule transport due to
loss of TBK1 could contribute to ALS by the impaired
maturation of autophagosomes into autophagolysosomes.
Several studies have attempted to characterize neuro-
pathological features associated with TBK1-ALS and
FTD, though overall the number of individuals examined
is still low. An ALS patient carrying a TBK1 mutation
has been found with both TDP-43 positive and p62 posi-
tive inclusions in motor neurons as well as TDP-43
inclusions in the cortex [64]. An FTD patient from the
same study was found to have TDP-43 inclusions in vari-
ous brain regions as well as cytoplasmic p62 and
ubiquitin-positive inclusions in glial cells [64]. Another
study found TDP-43 positive inclusions in three out of
five TBK1-FTD patients [17] and another found both
TDP-43 and p62 positive inclusions in various brain re-
gions of a TBK1-FTD/ALS patient [7]. These findings,
particularly of p62 and ubiquitin-positive inclusions,
provide further indications that TBK1 mutations may
contribute to ALS through impaired autophagy.
Mitophagy, TBK1 and ALS pathogenesis
Recent studies have identified important roles for TBK1
and other ALS genes in autophagy of mitochondria,
specifically known as mitophagy [48, 65]. In the PINK1-
Parkin pathway, PINK1 is able to detect damaged mito-
chondria by crossing the outer mitochondrial membrane
(OMM). If the mitochondrion is healthy, PINK1 passes
through the OMM and is degraded on the inner mitochon-
drial membrane (IMM). However, if the mitochondrion is
damaged PINK1 is retained on the OMM where it accumu-
lates and phosphorylates ubiquitin chains on several OMM
proteins resulting in binding of autophagy adaptors [48].
PINK1 concurrently recruits and phosphorylates Parkin,
resulting in its activation. Parkin is an E3 ubiquitin ligase
that constructs ubiquitin chains on OMM proteins, which
are then phosphorylated by PINK1, allowing further
adaptor binding [65]. TBK1 can then be activated by a
mechanism dependent on Parkin, OPTN, NDP52 and
OPTN-ubiquitin binding ability [48]. Activated TBK1 can
phosphorylate NDP52, OPTN, and p62, greatly enhancing
their ability to link ubiquitin and LC3-II [65]. Phosphoryl-
ation of OPTN enhances its ubiquitin binding ability and
its role in TBK1 activation resulting in a positive feedback
mechanism of TBK1 and OPTN activation [48, 65]. NDP52
and OPTN are able to bring about mitophagy by linking
ubiquitinated OMM proteins and LC3 proteins on phago-
phores resulting in engulfment and digestion of mitochon-
dria [26].
The role of p62 in mitophagy is controversial; several
studies have reported that p62 is not essential for mito-
phagy but plays a role in the aggregation of ubiquiti-
nated mitochondria [48, 65]. On the other hand, it has
also been reported that activation of p62 is required for
efficient mitophagy [66]. TBK1 is required for efficient
recruitment of autophagy adaptors and efficient mito-
phagy, and TBK1 is essential for mitophagy via OPTN
[48, 65]. Loss of TBK1 function would result in impaired
mitophagy and accumulation of defective mitochondria,
which may contribute to ALS by disrupting axonal
transport that occurs in ALS [67].
Recent studies have added further weight to the argu-
ment that TBK1 mutations contribute to ALS through
impaired autophagy/mitophagy. The E696K missense
mutation identified in ALS patients [7, 17] occurs in the
TBK1 CCD2 domain that interacts with adaptor proteins
such as OPTN. This mutation disrupts two hydrogen
bonds with H52 and K55 on the N-terminal domain of
OPTN, which in turn disrupts the OPTN-TBK1 complex.
Co-localization of TBK1 with OPTN is also reduced fol-
lowing the E696K mutation, with co-immunoprecipitation
studies showing that the mutation almost completely
abolishes the interaction between the two proteins [68].
Whilst wild-type TBK1 localizes to damaged mitochon-
dria, the E696K mutant exhibited severely reduced coloca-
lization with damaged mitochondria [69]. This suggests
that this process is dependent on OPTN, due to the loss
of TBK1-OPTN binding in the E696K mutant. This po-
tentially provides evidence that defective mitophagy is a
pathogenic mechanism in TBK1-ALS.
Tissue specificity and importance of age in TBK1-ALS
Autophagy can play one of two roles in the cell; to de-
grade proteins, regardless of cell stress, via continuous
operation at low levels (basal autophagy) or to supply
amino acids for cell survival during poor environmental
conditions (adaptive autophagy) [70]. Basal autophagy in
neuronal cells is crucial to their integrity. Most cells can
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dilute damaging agents through cell division, whereas
the post-mitotic nature of neuronal cells means that they
require autophagy to remove toxic proteins [71]. This
implies a high level of basal autophagy in these cells, an
idea supported by the high autophagic efficiency sug-
gested by the rarity of autophagic vacuoles in healthy
neurons [72]. Given the high level of autophagic activity
required for neuronal maintenance, it is not surprising
that these tissues are particularly susceptible to damage
through disruption of autophagy.
TBK1 is normally expressed diffusely in the cytoplasm
at moderate levels in all tissues but is expressed at a
much higher level in neuronal cells of the cerebral cor-
tex, hippocampus and lateral ventricle [73]. Moderate
TBK1 levels are also seen in the glial cells of the cerebral
cortex, Purkinje cells and granular layer cells in the
cerebellum [73]. ALS is characterized by loss of spinal,
cerebellar, hippocampal, brain stem and cortical motor
neurons [23], as well as a loss of pyramidal neurons in
the primary motor cortex. The fact that TBK1 expres-
sion is high in neurons of the CNS which are then lost
during ALS, may suggest that loss of function TBK1 mu-
tations may have a greater effect in these cells. TBK1 is
also highly expressed in various other tissues, including
the lungs, endocrine tissues and skin [73]. This begs the
question as to why the major effects of ALS are only ob-
served in nervous tissue. This may be explained by a
threshold for development of pathology that may not be
reached in these other tissues.
Advanced age appears to be an important factor in the
development of ALS and this may be due to a number
of factors. A reduction in the number of motor neurons
is a normal part of aging and this can contribute to
sarcopenia, the age-related loss of muscle mass [74]. In
addition to this, the uptake of heavy metals into spinal
cord neurons is also increased with advancing age [74];
exposure to heavy metals is a risk factor of ALS due to
increased glutamate excitotoxicity [3]. Recovery of motor
function is decreased in an aged ALS mouse model
when compared to their younger counterparts [75].
Finally, the rate of autophagy declines with age leading
to a reduction of the ability of cells to remove protein
aggregates [76], or indeed damaged mitochondria which
may be particularly detrimental to neurons. These factors
may contribute to the tissue specificity of TBK1 involve-
ment in ALS, regardless of its widespread expression. It is
unlikely that defects in TBK1 related pathways suddenly
appear at some point in the course of advancing age but
instead the threshold required to cause disease is lowered
to the point where these defects become pathological. In
other words, age-related factors such as sarcopenia, heavy
metal accumulation, and impaired neuronal recovery may
facilitate the progression of ALS due to defective TBK1
signaling.
Future outlook
TBK1 is involved in a variety of ALS-relevant pathways
such as autophagy and neuroinflammation. TBK1 func-
tion, pathological findings in ALS and known pathogenic
mechanisms of ALS point towards autophagy as the
major contribution of TBK1 mutations to ALS. Defective
autophagy may lead to the accumulation of protein ag-
gregates, autophagosomes and damaged mitochondria in
motor neurons. This may all result in impaired axonal
transport of molecules and organelles, such as mito-
chondria, which are crucial for neuron function and sur-
vival. Given the varied and crucial roles of TBK1 in
autophagy and mitophagy, it seems that these mecha-
nisms may be paramount in the contribution of TBK1 to
ALS pathogenesis. Impaired mitochondrial function and
transport may result in neuronal damage by the mecha-
nisms discussed above. Neuronal damage may trigger in-
nate responses by cells surrounding neurons leading to
neuroinflammation, another important mechanism in
ALS pathogenesis. Further dissection of TBK1 signaling
pathways in neurons will help further our understanding
of the contribution of TBK1 mutations to ALS. Given a
large number of downstream targets of TBK1 that have
been identified, relatively few have been investigated
thoroughly. Studies comparing the pathological findings
in different ALS genotypes may also aid our understand-
ing of how different genes/pathways contribute to ALS.
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